Search "compounded semaglutide" and you'll find programs promising "the same active ingredient as Ozempic." That's the part that can be true. Compounded semaglutide is made by a pharmacy for a patient, from semaglutide it buys as a raw ingredient. Ozempic is a finished, FDA-approved product with a fixed formula. The table shows where they part ways.
Same molecule name, different product
| Ozempic or Wegovy | Compounded semaglutide | |
|---|---|---|
| FDA-approved? | Yes (Ozempic 2017, Wegovy 2021) | No |
| Who makes it | Novo Nordisk, under its approved application | A compounding pharmacy, per prescription |
| Active ingredient | Semaglutide, as named on the label | Semaglutide, or sometimes a salt form FDA says isn't lawful to compound |
| Added ingredients | Only the listed inactive ingredients | Often B12, B6, glycine or other add-ins chosen by the pharmacy |
| Device | Prefilled pens with set doses; Wegovy also as tablets | Usually a multi-dose vial and syringes |
| Trial evidence | SUSTAIN and STEP programs, among others | None for any compounded product |
| FDA quality review before sale | Yes | No |
| Adverse-event reports | Collected under standard drug-safety rules; listed on the label | 990 reports to FDA as of May 31, 2026; likely underreported |
| Legal path today | Any prescription | Patient-specific, within FDA's narrow limits |
| Self-pay price | NovoCare: Wegovy pen $349, pill $149 to $299; Ozempic pen $349 (up to 1 mg) or $499 (2 mg) | $75–$349/mo at telehealth programs |
| Insurance | Possible, depending on your plan and diagnosis | Generally not covered |
Brand rows from the Ozempic (version 20) and Wegovy (version 19) labels on DailyMed and NovoCare's self-pay pages; FDA rows from its GLP-1 concerns page, current as of October 1, 2026.
Ozempic or Wegovy: which brand is the fair comparison
People search for "compounded semaglutide vs Ozempic" because Ozempic is the famous name. But most compounded semaglutide is sold for weight loss, and Ozempic's label is for type 2 diabetes: blood-sugar control plus heart and kidney protection [4]. The brand labeled for weight is Wegovy, which also goes to higher doses [5].
So for most readers, the like-for-like comparison is compounded semaglutide against Wegovy. Everything on this page applies to both brands, since they share the molecule and the maker. How the two brands differ is in Ozempic vs Wegovy.
Oversight: FDA checks the brand, not the compounded version
However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.[1]
That review is what approval means. FDA's view is that compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug" [1].
That's also roughly what federal law allows now. Under section 503A, FDA says it won't act against a pharmacy that fills four or fewer prescriptions a month of a drug that's essentially a copy of Ozempic or Wegovy. The exception is when a prescriber documents that a change in the compounded version makes a significant difference for an identified patient [2].
What's in the vial depends on the pharmacy
Ozempic and Wegovy contain semaglutide in the form named on their labels, made to one approved specification [4]. Compounded products vary. FDA says some contain salt forms instead:
These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding.[1]
Add-ins are common too. In 2025, researchers posing as patients approached 75 weight-loss businesses across two states, West Virginia and Oklahoma; 56.0% sold compounded GLP-1 products mixed with B vitamins. Four of the 21 supplying pharmacies they could look up held no sterile-compounding license [10].
Lab work points the same way. A 2026 analysis found compounded semaglutide samples had different impurity profiles from the brand, and big differences in strength and impurities after light exposure. The authors are Novo Nordisk employees, Ozempic's maker, and the work was done in lab tests, not in patients [11].
Evidence: the trials belong to the brand
Ozempic's heart-risk label rests on SUSTAIN-6, where semaglutide cut heart attack, stroke or heart death to 6.6% against 8.9% on placebo [8]. Wegovy's weight label rests on trials like STEP 1: 14.9% average weight loss at 68 weeks against 2.4% [9].
Those results were earned by those exact products. No compounded semaglutide product has been tested in a published trial, so nobody can say its results match. When people ask whether Wegovy is better than compounded semaglutide, the fair answer is that Wegovy is the one with evidence. The research is reviewed in does compounded semaglutide work.
Safety reports and dosing errors
FDA's count stood at 990 side-effect reports linked to compounded semaglutide on May 31, 2026 [1]. Because most compounding pharmacies aren't required to report adverse events to FDA, the agency says the real number is likely higher.
FDA has also flagged reports, some needing hospital care, linked to dosing errors with compounded injections: errors that came from people measuring and injecting the wrong amount from a vial [1]. And it has found fraudulent products whose labels named pharmacies that don't exist. More on safety in is compounded semaglutide safe.
Pens with set doses vs a vial you draw from
Ozempic and Wegovy come in prefilled pens that deliver fixed doses in milligrams, and Wegovy also comes as a tablet [4] [5]. There's nothing to measure.
Compounded semaglutide usually ships as a multi-dose vial, and the strength varies from pharmacy to pharmacy. FDA recommends using a multi-dose vial within 28 days of first use because the contamination risk rises after that [1]. If you're prescribed a compounded product, your prescriber and pharmacy explain the dose and how to measure it; don't rely on a chart from another source.
Cost: the gap has narrowed
Compounded semaglutide took off while the brand was in shortage and had no low-cost self-pay option. Novo Nordisk's direct prices have changed that.
| Option | Form | Monthly cost |
|---|---|---|
| CollectivePartner | Compounded injection | $75.58/moMedication monthly plus a required yearly membership |
| EmbodyPartner | Compounded injection | $86/moEvery 4 weeks |
| EdenPartner | Compounded injection | $99/moMonthly, same price at every dose |
| LttlPartner | Compounded injection | $107.25/moMonthly auto-refill |
| Strut HealthPartner | Compounded injection | $129/moMonthly auto-refill |
| CoreAge RxPartner | Compounded injection | $139/moMonthly, or multi-month packages |
| Brightmeds | Compounded injection | $139.75/moEvery 4 weeks, month to month |
| HealthRxPartner | Compounded injection | $165/moMonthly after an intro month, or prepaid |
| ShedPartner | Compounded injection | $215.58/moMonth to month |
| GalaPartner | Compounded injection | $249/moMonthly, quarterly or yearly |
| Wegovy pen, NovoCare | Brand injection | $349 (after two $199 starter fills for new patients)Monthly |
| Wegovy pill, NovoCare | Brand tablet | $149 to $299 by tablet strengthMonthly, 30 tablets |
| Ozempic pen, NovoCare | Brand injection | $349 (up to 1 mg) or $499 (2 mg)Monthly |
Brand prices from NovoCare, which says pricing will be updated after December 31, 2026. Program prices from each provider's own site, as a full monthly cost including required fees.
Also offered by (no standing monthly price published): Midi Health.
At the low end, compounded programs still cost less than the brand. The typical program charges $199 a month, against $149 to $299 for the Wegovy pill, which comes with FDA review and trial data [6]. Every program's price is in the compounded semaglutide cost guide, programs are compared beyond price in compounded semaglutide programs, scored, and how to get compounded semaglutide covers the prescription steps.
Legal status, briefly
The semaglutide shortage officially ended on February 21, 2025, by FDA's determination [2]. State-licensed pharmacies lost their shortage-era allowance after a federal court denied an injunction on April 24, 2025; outsourcing facilities lost theirs after May 22, 2025. Semaglutide isn't on FDA's shortage list or its 503B bulks list [2].
On May 1, 2026, FDA formally proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list for good. The public comment window ran until July 30, 2026; as of this update FDA still hasn't issued its final call [3]. What that could mean is in will compounded semaglutide be banned. The tirzepatide version of this comparison is compounded tirzepatide vs Zepbound.